SOUTH SAN FRANCISCO, Calif., March 11, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB) today announced that the Company received a letter on March 5, 2009 from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff Determination") notifying the Company that, based upon its non-compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Marketplace Rule 4310(c)(3), the Company's securities were subject to delisting from NASDAQ unless the Company requested a hearing before a NASDAQ Listing Qualifications Panel (the "NASDAQ Panel").
